Dermatology Advocacy Groups May Not Disclose Conflicts Dermatology Advocacy Groups May Not Disclose Conflicts
Many patient advocacy groups focused on skin conditions receive funding from companies that sell dermatology treatments, and a new study suggests these nonprofits don't always disclose their ties to industry.Reuters Health Information
ConclusionsThis study indicates that a substantial proportion of subjects with OA experience severe asthma and identifies potentially modifiable risk factors for severe OA that should be targeted in order to reduce the adverse impacts of the disease.
(MedPage Today) -- New evidence also presented on breastfeeding and development of atopic disease, asthma
Publication date: Available online 23 March 2019Source: Journal of Food Composition and AnalysisAuthor(s): Katsunari Ippoushi, Yoshimi Tanaka, Manabu Wakagi, Naoto Hashimoto, Yuko Takano-IshikawaAbstractPru p 1 and Pru p 3 are proteins found in peach (Prunus persica (L.) Batsch), and they are members of the pathogenesis-related protein 10 (PR-10) and non-specific lipid transfer protein (nsLTP) families, respectively. They are the main allergens of peach. In this paper, we describe a quantitative method for these proteins based on protein absolute quantification with liquid chromatography–tandem mass spectrometry, and...
Giving thyroid hormone replacement before conception didn't prevent miscarriages or other adverse pregnancy outcomes in euthyroid women with thyroid peroxidase antibodies, shows the TABLET trial.Medscape Medical News
This study aimed to investigate whether subcutaneous immunotherapy (SCIT) with Fagales pollen-containing extracts can improve the clinical symptoms of OAS in Korea. In total, 56 OAS patients were included: 19 subjects treated with SCIT, which included Fagales pollen extracts, and 37 not treated with immunotherapy (IT). We reviewed the patients' medical records and administered a telephone questionnaire at one point to assess baseline OAS features and changes in the patients' OAS and allergic rhinoconjunctivitis (ARC) symptoms after treatment. Only 12 patients who received SCIT and 15 patients that did not receive SCIT coul...
Publication date: Available online 23 March 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Pooja Mehta, Zhaoxing Pan, Glenn T. Furuta, Bethany M. Kwan
Publication date: Available online 23 March 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Michele N. Pham, Michael Pistiner, Julie Wang
Publication date: Available online 22 March 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Salma Alkhammash, Harmony Tsui, David M.P. Thomson
Publication date: Available online 22 March 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Lucy A. Bilaver, Hemant P. Sharma, Ruchi S. Gupta, Linda J. Herbert, Mary Jane Marchisotto, Ozge N. Aktas, Jialing Jiang, Emily Miller
CONCLUSIONS: Our study evaluating patients with ACS or stable CAD undergoing PCI and treated with mono anti-platelet therapy with P2Y12 inhibitors due to aspirin intolerance shows a 25% incidence of POCE at one year. Further studies with adequate sample size are required to evaluate the efficacy and safety of mono anti-platelet therapy in this clinical scenario. PMID: 30895761 [PubMed - as supplied by publisher]